Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at det samlede mønster i resulta - terne af undersøgelserne med Xolair viser, at det er effektivt til behandling af svær allergisk astma, trods resultaterne af den afsluttende hovedundersøgelse.
The Committee for Medicinal products for Human Use (CHMP) concluded that, overall, there was a pattern of results in the studies of Xolair that show that it is effective in treating severe allergic asthma, despite the results of the final main study.